Ribocure supports WORLD KIDNEY DAY on March 14th

Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA).

Across the globe, chronic kidney disease (CKD) affects around 700 million people, with 3.1 million deaths attributable to kidney dysfunction, making it the seventh leading cause of mortality worldwide.

Low- and middle-income countries bear a disproportionate burden of CKD and kidney failure.

Multiple determinants including socioeconomic, cultural, environmental, and political factors contribute to the disparity in disease burden across the globe.

In lower resource contexts, access to and affordable and quality kidney care are particularly challenging, contributing to premature deaths of millions of people.